Therapeutic Indications Of KADCYLA
used to treat breast cancer in adults when:
∙ the cancer cells have many HER2 proteins on them - your doctor will test your cancer cells for this.
∙ the cancer has spread to areas near the breast or to other parts of your body (metastasised)
∙ you have already received the medicine trastuzumab and a medicine known as a taxane.
∙ the cancer has not spread to other parts of the body and treatment is going to be given after surgery (treatment after surgery is called adjuvant therapy) for patients who still have a residual invasive disease despite being treated by other neoadjuvant anti-cancer medications (taxane and trastuzumab -based treatment (treatment before surgery is called neoadjuvant therapy).
Method Of Administration Of Kadcyla
∙ It is given by a drip into a vein (intravenous infusion).
∙ You will be given one infusion every 3 weeks.
How much you will be given
∙ You will be given 3.6 mg of Kadcyla for every kilogram of your body weight. Your doctor will calculate the correct dose for you.
∙ The first infusion will be given to you over 90 minutes. You will be observed by a doctor or nurse while it is being given and for at least 90 minutes following the initial dose, in case you have any side effects.
∙ If the first infusion is well tolerated, the infusion on your next visit may be given over 30 minutes. You will be observed by a doctor or nurse while it is being given and for at least 30 minutes following the dose, in case you have any side effects.
∙ The number of infusions you will be given depends on how you respond to treatment and type of cancer (if the disease has spread or not).
Undesirable Side Effects Of Kadcyla
Like all medicines, this medicine can cause side effects, although not everybody gets them.
. may cause inflammation or damage to cells in the liver, resulting in elevated liver enzymes in blood tests. However, in most cases during Kadcyla treatment, liver enzyme levels are elevated mildly and temporarily, do not cause any symptoms, and do not affect liver function.
∙ Tingling, pain, numbness, itching, crawling sensation, pins and needles in your hands and feet. These symptoms may indicate nerve damage.
∙ Flushing, shivering fits, fever, trouble breathing, low blood pressure or a rapid heartbeat during the infusion or up to 24 hours after the infusion – these are so-called infusion-related reactions.
Warnings & Special Precautions While Taking Kadcyla
∙ you have ever had a serious infusion-related reaction from using trastuzumab characterised by symptoms such as flushing, chills, fever, shortness of breath, difficulty breathing, rapid heartbeat or a drop in blood pressure.
∙ you are receiving treatment with blood thinning medicines (e.g. warfarin, heparin).
∙ you have any history of liver problems. Your doctor will check your blood to test your liver function before and regularly during treatment.
Storage Conditions Of Kadcyla
∙ Keep this medicine out of the sight and reach of children.
∙ Do not use this medicine after the expiry date which is stated on the outer carton after EXP. The expiry date refers to the last day of that month.
∙ Store in a refrigerator at (2°C 8°C). Do not freeze.
∙ When prepared as a solution for infusion Kadcyla is stable for up to 24 hours at 2°C to 8°C, and must be discarded thereafter.
∙ Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.